The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Restricted accessReview articleFirst published online April, 2010
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.
Uccelli A., Pistoia V., Moretta L.Mesenchymal stem cells: a new strategy for immunosuppression?Trends Immunol2007; 28: 219-226.
2.
Karussis D. , Kassis I., Kurkalli BG, Slavin S.Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/ neurodegenerative diseases. J Neurol Sci2008 ; 265(1-2): 131-135.
3.
Pluchino S. , Martino G.The therapeutic plasticity of neural stem/precursor cells in multiple sclerosis . J Neurol Sci2008; 265(1-2): 105-110.
4.
Scolding N. , Marks D., Rice C.Autologous mesenchymal bone marrow stem cells: practical considerations. J Neurol Sci2008; 265(1-2): 111-115.
Uccelli A., Moretta L., Pistoia V.Mesenchymal stem cells in health and disease. Nat Rev Immunol2008; 8(9): 726-736.
7.
Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet2008; 371(9624): 1579-1586.
8.
Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med1999; 5(3): 309-313.
9.
Koc ON, Day J., Nieder M., Gerson SL, Lazarus HM, Krivit W.Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant2002; 30(4): 215-222.
10.
Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol2000; 18(2): 307-316.
11.
Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant2005 ; 11(5): 389-398.
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AIEx vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant1995 /10; 16(4): 557-564.
14.
Horwitz EM, Gordon PL, Koo WKK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A2002; 99(13): 8932-8937.
15.
Tolar J., Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells2007; 25(2): 371-379.
16.
Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood2005; 106(5): 1755-1761.
17.
Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol2005; 195(1): 16-26.
18.
Gerdoni E., Gallo B., Casazza S., et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol2007; 61(3): 219-227.
19.
Bai L., Lennon DP, Eaton V., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia2009; 57(11): 1192-1203.
20.
Gordon D., Pavlovska G., Glover CP, Uney JB, Wraith D., Scolding NJHuman mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett2008; 448(1): 71-73.
21.
Kassis I., Grigoriadis N., Gowda-Kurkalli B., et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol2008; 65(6): 753-761.
22.
Rafei M., Campeau PM, Aguilar-Mahecha A., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol2009; 182(10): 5994-6002.
23.
Zhang J., Li Y., Lu M., et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res2006; 84(3): 587-595.
24.
Crigler L., Robey RC, Asawachaicharn A., Gaupp D., Phinney DGHuman mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol2006; 198(1): 54-64.
25.
Lanza C., Morando S., Voci A., et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem2009 ; 110(5): 1674-1684.
26.
Wilkins A., Kemp K., Ginty M., Hares K., Mallam E., Scolding N.Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res2009; 3(1): 63-70.
27.
Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJHuman stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A2005; 102(50): 18171-18176.
28.
Akiyama Y., Radtke C., Kocsis J.Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J Neurosci2002 ; 22(15): 6623-6630.
Phinney DG, Prockop DJConcise review: mesenchymal stem/multi-potent stromal cells (MSCS): the state of transdifferentiation and modes of tissue repair - current views . Stem Cells2007; 25(11): 2896-2902.
31.
Mohyeddin Bonab M., Yazdanbakhsh S., Lotfi J., et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study . Iran J Immunol2007; 4(1): 50-57.
32.
Tyndall A., Uccelli A.Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. Bone Marrow Transplant2009 ; 43(11): 821-828.
33.
Mancardi G. , Saccardi R.Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol2008; 7(7): 626-636.
34.
Mancardi GL , Saccardi R., Filippi M., et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology2001; 57(1): 62-68.
